GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Eyenovia Inc (NAS:EYEN) » Definitions » Cyclically Adjusted Price-to-FCF

EYEN (Eyenovia) Cyclically Adjusted Price-to-FCF : (As of Jun. 03, 2025)


View and export this data going back to 2018. Start your Free Trial

What is Eyenovia Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Eyenovia Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Eyenovia's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Eyenovia Cyclically Adjusted Price-to-FCF Chart

Eyenovia Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Eyenovia Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Eyenovia's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Eyenovia's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Eyenovia's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Eyenovia's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Eyenovia's Cyclically Adjusted Price-to-FCF falls into.


;
;

Eyenovia Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Eyenovia's Cyclically Adjusted FCF per Share for the fiscal year that ended in Dec24 is calculated as:

For example, Eyenovia's adjusted Free Cash Flow per Share data for the fiscal year that ended in Dec24 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Dec24 (Change)*Current CPI (Dec24)
=-36.353/133.1571*133.1571
=-36.353

Current CPI (Dec24) = 133.1571.

Eyenovia Annual Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201512 -30.935 99.792 -41.278
201612 -26.185 101.863 -34.230
201712 -38.234 104.011 -48.948
201812 -111.347 105.998 -139.877
201912 -106.626 108.420 -130.954
202012 -25.266 109.897 -30.614
202112 -68.368 117.630 -77.393
202212 -61.710 125.222 -65.621
202312 -54.207 129.419 -55.773
202412 -36.353 133.157 -36.353

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Eyenovia  (NAS:EYEN) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Eyenovia Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Eyenovia's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Eyenovia Business Description

Industry
Traded in Other Exchanges
N/A
Address
23461 South Point Drive, Suite 390, Laguna Hills, CA, USA, 92653
Eyenovia Inc is a clinical-stage ophthalmic company developing a pipeline of therapeutics based on its proprietary array print (MAP) platform technology. It aims to achieve clinical microdosing of next-generation formulations of novel and existing ophthalmic pharmaceutical agents using its high-precision targeted ocular delivery system, branded the Optejet, which has the potential to replace conventional eye dropper delivery and improve safety, tolerability, patient compliance, and topical delivery success for ophthalmic eye treatments. Using its proprietary delivery technology, Eyenovia is developing the next generation of smart ophthalmic therapies that target new indications or new combinations.
Executives
Michael M Rowe director, officer: Chief Executive Officer C/O EYENOVIA, INC., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stuart M. Grant 10 percent owner 11 SUMMIT LANE, GREENVILLE DE 19807
Ellen R Strahlman director ALTRIA GROUP, INC., 6601 W. BROAD STREET, RICHMOND VA 23230
Ram Palanki director C/O EYENOVIA, INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
Rachel Jacobson director C/O EYENOVIA INC, 295 MADISON AVENUE SUITE 2400, NEW YORK NY 10017
John P Gandolfo officer: Chief Financial Officer 62 TERRACE ROAD, WAYNE NJ 07470
Bren Kern officer: Chief Operating Officer 295 MADISON AVENUE, SUITE 2400, C/O EYENOVIA, INC., NEW YORK NY 10017
Mather Charles E Iv director C/O TONIX PHARMACEUTICALS HOLDING CORP, 509 MADISON AVE., SUITE 306, NEW YORK NY 10022
Tsontcho Ianchulev director 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017
Stephen Keith Benjamin director 135 NORTH CHURCH STREET, SPARTANBURG SC 29306
Julia A Haller director C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Lee Kenneth B Jr director 7100 WEST CREDIT AVENUE, SUITE 101, C/O ARALEZ PHARMACEUTICALS INC., MISSISSAUGA A6 L5N 0E4
Curt H Labelle director C/O INVESTOR GROWTH CAPITAL, INC., 630 FIFTH AVENUE, SUITE 1965, NEW YORK NY 10011
Anthony Y Sun director C/O AISLING CAPITAL, 888 SEVENTH AVENUE, 30TH FLOOR, NEW YORK NY 10106
Fredric N Eshelman director PPD INC, 929 NORTH FRONT STREET, WILMINGTON NC 28401